Fixed-dose combination therapy for Parkinson’s disease with a spotlight on entacapone in the past 20 years: a reduced pill burden and a simplified dosing regime

References

• Beitz JM. Parkinson’s disease: a review. Front Biosci (Schol Ed). 2014;6:65–74.
   PubMedGoogle Scholar
• Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386:896–912.
   PubMed Web of Science ®Google Scholar
• Dickson DW. Neuropathology of Parkinson disease. Parkinsonism Relat Disord. 2018;46:S30–S33.
   PubMed Web of Science ®Google Scholar
• Salamon A, Zádori D, Szpisjak L, et al. Neuroprotection in Parkinson’s disease: facts and hopes. J Neural Transm (Vienna). 2019. DOI:10.1007/s00702-019-02115-8.
   PubMed Web of Science ®Google Scholar
• Dietrichs E, Odin P. Algorithms for the treatment of motor problems in Parkinson’s disease. Acta Neurol Scand. 2017;136:378–385.
   PubMed Web of Science ®Google Scholar
• Marsala SZ, Gioulis M, Ceravolo R, et al. A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice. Clin Neuropharmacol. 2012;35:185–190.
   PubMed Web of Science ®Google Scholar
• Annus Á, Vécsei L. Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy. Drug Des Devel Ther. 2017;11:143–151.
   PubMed Web of Science ®Google Scholar
• Salamon A, Zádori D, Szpisjak L, et al. Opicapone for the treatment of Parkinson’s disease: an update. Expert Opin Pharmacother. 2019;20:2201–2207.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Healy DG, Schapira AH, et al. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5:235–245.
   PubMed Web of Science ®Google Scholar
• Palmer CS, Nuijten MJ, Schmier JK, et al. Cost effectiveness of treatment of Parkinson’s disease with entacapone in the United States. Pharmacoeconomics. 2002;20:617–628.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
   PubMed Web of Science ®Google Scholar
• Linazasoro G, Kulisevsky J, Hernández B, et al. Should levodopa dose be reduced when switched to stalevo? Eur J Neurol. 2008;15:257–261.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Jennings D, Lyons KE, et al. Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. Mov Disord. 2009;24:1319–1324.
   PubMed Web of Science ®Google Scholar
• Kuoppamäki M, Leinonen M, Poewe W. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off. J Neural Transm (Vienna). 2015;122:1709–1714.
   PubMed Web of Science ®Google Scholar
• Park J, Kim Y, Youn J, et al. Levodopa dose maintenance or reduction in patients with Parkinson’s disease transitioning to levodopa/carbidopa/entacapone. Neurol India. 2017;65:746–751.
   PubMed Web of Science ®Google Scholar
• Iwaki H, Nishikawa N, Nagai M, et al. Pharmacokinetics of levodopa/benserazide versus levodopa/carbidopa in healthy subjects and patients with Parkinson’s disease. Neurol Clin Neurosci. 2015;3:68–73.
   Web of Science ®Google Scholar
• Heikkinen H, Varhe A, Laine T, et al. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose. Br J Clin Pharmacol. 2002;54:363–371.
   PubMed Web of Science ®Google Scholar
• Paija O, Laine K, Kultalahti ER, et al. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. Clin Neuropharmacol. 2005;28:115–119.
   PubMed Web of Science ®Google Scholar
• Kuoppamäki M, Korpela K, Marttila R, et al. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur J Clin Pharmacol. 2009;65:443–455.
   PubMed Web of Science ®Google Scholar
• Müller T, Erdmann C, Muhlack S, et al. Pharmacokinetic ehavior of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease. J Neural Transm (Vienna). 2006;113:1441–1448.
   PubMed Web of Science ®Google Scholar
• Müller T, Erdmann C, Muhlack S, et al. Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. Mov Disord. 2006;21:332–336.
   PubMed Web of Science ®Google Scholar
• Müller T, Ander L, Kolf K, et al. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson’s disease. J Neural Transm (Vienna). 2007;114:1457–1462.
   PubMed Web of Science ®Google Scholar
• Müller T, Erdmann C, Muhlack S, et al. Entacapone improves complex movement performance in patients with Parkinson’s disease. J Clin Neurosci. 2007;14:424–428.
   PubMed Web of Science ®Google Scholar
• Stocchi F, Barbato L, Nordera G, et al. Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson’s patients. J Neural Transm (Vienna). 2004;111:173–180.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Panisset M, Abbruzzese G, et al. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson’s disease. Mov Disord. 2009;24:541–550.
   PubMed Web of Science ®Google Scholar
• Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68:18–27.
   PubMed Web of Science ®Google Scholar
• Lyons KE, Pahwa R. Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients. Clin Neuropharmacol. 2006;29:73–76.
   PubMed Web of Science ®Google Scholar
• Myllylä V, Haapaniemi T, Kaakkola S, et al. Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study). Acta Neurol Scand. 2006;114:181–186.
   PubMed Web of Science ®Google Scholar
• Boiko AN, Batysheva TT, Minaeva NG, et al. Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson’s disease in out-patient clinical practice (the START-M open trial). Neurosci Behav Physiol. 2008;38:933–936.
   PubMedGoogle Scholar
• Olanow CW, Kieburtz K, Stern M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol. 2004;61:1563–1568.
   PubMed Web of Science ®Google Scholar
• Fung VS, Herawati L, Wan Y, et al. Quality of life in early Parkinson’s disease treated with levodopa/carbidopa/entacapone. Mov Disord. 2009;24:25–31.
   PubMed Web of Science ®Google Scholar
• Brooks DJ, Agid Y, Eggert K, et al. Treatment of end-of-dose wearing-off in parkinson’s disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur Neurol. 2005;53:197–202.
   PubMed Web of Science ®Google Scholar
• Koller W, Guarnieri M, Hubble J, et al. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson’s disease patients experiencing wearing-off. J Neural Transm (Vienna). 2005;112:221–230.
   PubMed Web of Science ®Google Scholar
• Eggert K, Skogar O, Amar K, et al. Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson’s disease patients with wearing-off: efficacy, safety and feasibility–an open-label, 6-week study. J Neural Transm (Vienna). 2010;117:333–342.
   PubMed Web of Science ®Google Scholar
• Lew MF, Somogyi M, McCague K, et al. Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson’s disease with end-of-dose wearing off. Int J Neurosci. 2011;121:605–613.
   PubMed Web of Science ®Google Scholar
• Delea TE, Thomas SK, Hagiwara M, et al. Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson’s disease. Curr Med Res Opin. 2010;26:1543–1552.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord. 2009;24:2175–2186.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Emre M, Dubois B. Parkinson’s disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann Neurol. 2008;64:(S.2):81–92.
   PubMed Web of Science ®Google Scholar
• Insel K, Morrow D, Brewer B, et al. Executive function, working memory, and medication adherence among older adults. J Gerontol B Psychol Sci Soc Sci. 2006;61:102–107.
   PubMed Web of Science ®Google Scholar
• Stoehr GP, Lu SY, Lavery L, et al. Factors associated with adherence to medication regimens in older primary care patients: the Steel Valley Seniors Survey. Am J Geriatr Pharmacother. 2008;6:255–263.
   PubMed Web of Science ®Google Scholar
• Piccini P, Brooks DJ, Korpela K, et al. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2000;68:589–594.
   PubMed Web of Science ®Google Scholar
• Müller T, Kolf K, Ander L, et al. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease. Clin Neuropharmacol. 2008;31:134–140.
   PubMed Web of Science ®Google Scholar
• Tolosa E, Hernández B, Linazasoro G, et al. Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson’s disease experiencing mild wearing-off: a randomised, double-blind trial. J Neural Transm (Vienna). 2014;121:357–366.
   PubMed Web of Science ®Google Scholar
• Hsu A, Yao HM, Gupta S, et al. Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)). J Clin Pharmacol. 2015;55:995–1003.
   PubMed Web of Science ®Google Scholar
• Antonini A, Stoessl AJ, Kleinman LS, et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach. Curr Med Res Opin. 2018;34:2063–2073.
   PubMed Web of Science ®Google Scholar